Anixa Biosciences Q2 EPS beats estimates, losses narrow
Anixa Biosciences reported Q2 EPS of $(0.07), beating the $(0.09) estimate by 22.22%. Losses narrowed 22.22% year-over-year from $(0.09) per share.
*this image is generated using AI for illustrative purposes only.
Anixa Biosciences reported quarterly losses of $(0.07) per share, surpassing the analyst consensus estimate of $(0.09) by 22.22%. The performance marks a 22.22% improvement in losses compared to $(0.09) per share recorded in the same period last year.
The company's earnings per share (EPS) for the quarter exceeded analyst expectations, reflecting a narrowing of losses on a year-over-year basis. The consensus estimate projected a loss of $(0.09) per share, while the actual reported loss was $(0.07) per share.
Financial Performance
The following table outlines the key earnings metrics for the reported quarter:
| Metric | Value |
|---|---|
| Reported EPS | $(0.07) |
| Consensus Estimate | $(0.09) |
| Year-Ago EPS | $(0.09) |
| Beat Estimate | 22.22% |
| YoY Change | 22.22% |
Anixa Biosciences' ability to reduce its per-share loss compared to the prior year and analyst projections highlights its progress in managing operational efficiency during the quarter.
What specific operational efficiency measures contributed most to the narrowing of losses?
When does Anixa Biosciences expect to achieve profitability based on current trends?
Are there any upcoming clinical trial milestones that could impact future financial performance?
16
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
